Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia

WeiDe Zhong; Jinyu Peng; HuiChan He; Dinglan Wu; ZhaoDong Han; XueCheng Bi; QiShan Dai
February 2008
Clinical & Investigative Medicine;Feb2008, Vol. 31 Issue 1, pE8
Academic Journal
Objective: Ki-67 is a proliferation-associated nuclear antigen and is expressed in all cycling cells except for resting cells in the G0-phase. PCNA is an acidic nuclear protein and has been recognized as a histologic marker for the G1/S phase in the cell cycle. Ki-67and PCNA labeling indices are considered to reflect cell proliferation, particularly, growth fraction. The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa. Methods: Human prostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Then, the association of Ki-67 and PCNA expression with clinical grading of PCa was analyzed by immunohistochemistry staining. Results: The ratios of PCNA and Ki-67 expression levels in LNCaP and PC-3 were higher (P<0.05, P<0.001) than that in HuPEC. The two markers were differentially expressed in three tissues and showed increased expression in PCa (P<0.05) and BPH (P<0.05), relative to human normal prostate tissues. Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P<0.05). The increase of Ki-67 was greater than that of PCNA. Expression of the two markers increased after different grading of PCa cases. The values of Ki-67/PCNA were: 0.073 in grade I PCa tissues, 0.119 in grade IIa PCa tissues, 0.141 in grade IIa PCa tissues, 0.234 in grade III PCa tissues. Conclusion: The combination of Ki-67 and PCNA, specific proliferative markers of PCa, may improve the accuracy of early diagnosis of prostatic cancer.


Related Articles

  • Ejaculatory Disorders Caused by Alpha-1 Blockers for Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Comparison of Naftopidil and Tamsulosin in a Randomized Multicenter Study. Masumori, Naoya; Tsukamoto, Taiji; Iwasawa, Akihiko; Furuya, Ryoji; Sonoda, Tomoko; Mori, Mitsuru // Urologia Internationalis;Jul2009, Vol. 83 Issue 1, p49 

    Introduction: To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Materials and Methods: Ninety-five patients with LUTS/BPH who had International Prostate...

  • Prostate Cancer Versus Enlarged Prostate.  // Tufts University Health & Nutrition Letter;Nov2001, Vol. 19 Issue 9, p6 

    Compares prostate cancer from an enlarged prostate gland. Symptoms of an enlarged prostate; Key for the cure of prostate cancer; Components of the prostate cancer screening test.

  • Benign prostatic hyperplasia and prostate cancer. Hikal, Ahmed H.; Hikal, Ethel M. // Drug Topics;7/6/98, Vol. 142 Issue 13, p62 

    Provides information on benign prostatic hyperplasia and prostate cancer. How these conditions have distinctive characteristics and are prevalent in men as they increase in age; Description of the prostate; Symptomology of both conditions; How diagnosis for both conditions is ascertained;...

  • Two PSA measures help differentiate prostate cancer from BPH. Kochlanska-Dziurowicz, A.A.; Mielniczuk, M.R. // Geriatrics;Oct98, Vol. 53 Issue 10, p88 

    Reports that according to a Polish study, the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer can be determined by using two methods of prostate specific antigen (PSA) ratio. Identification of the two methods of PSA; Operation of the two different types of PSAs;...

  • GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer. Naiki, Taku; Naiki-Ito, Aya; Asamoto, Makoto; Kawai, Noriyasu; Tozawa, Keiichi; Etani, Toshiki; Sato, Shinya; Suzuki, Shugo; Shirai, Tomoyuki; Kohri, Kenjiro; Takahashi, Satoru // Carcinogenesis;Sep2014, Vol. 35 Issue 9, p1962 

    GPX2 overexpression in CRPC increased cell growth through ROS regulation in a cell cycle-dependent manner. Moreover, patients with highly expressed GPX2 had significantly poorer prognosis. These findings suggest that GPX2 may be a prognostic marker and therapeutic target for CRPC.There is a need...

  • Methylation Pattern Of MGMT Gene In Relation To Age, Smoking, Drinking And Dietary Habits As Epigenetic Biomarker In Prostate Cancer Patients. Sidhu, Sukhjeet; Deep, Jagdeep S.; Sobti, R. C.; Sharma, V. L.; Thakur, Hitender // Genetic Engineering & Biotechnology Journal;Dec2010, p1 

    Epigenetic control of gene transcription is an important step for normal human development and cellular differentiation. Although alterations in DNA methylation pattern is a well-defined epigenetic change linked to human cancers and other diseases., inter-individual epigenetic variations in...

  • uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. Böhm, Lothar; Serafin, Antonio; Akudugu, John; Fernandez, Pedro; Merwe, Andre; Aziz, Naseem // Journal of Cancer Research & Clinical Oncology;Jul2013, Vol. 139 Issue 7, p1221 

    Purpose: Urokinase plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) are associated with tumour metabolism and are widely considered to be informative for the identification of cancer. We have analysed prostate tissue resections from patients with prostate cancer (PCa) and with benign...

  • Effect of Serenoa repens (PermixonW) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. Silvestri, Ida; Cattarino, Susanna; Aglianò, AnnaMaria; Nicolazzo, Chiara; Scarpa, Susanna; Salciccia, Stefano; Frati, Luigi; Gentile, Vincenzo; Sciarra, Alessandro // Journal of Inflammation;2013, Vol. 10 Issue 1, p1 

    Background: To analyze the expression at basal level of inflammation-related cytokines and chemokines and the activation status of the NF-κB pathway, together with the proliferation and apoptosis indexes in two widely used in vitro tumor models, the androgen-dependent human Prostate Cancer...

  • Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients. Cvetković, B.; Vučić, V.; Cvetković, Z.; Popović, T.; Glibetić, M. // Medical Oncology;Jun2012, Vol. 29 Issue 2, p809 

    The relationship between plasma levels of total phospholipids (PL) and/or PL fractions and neoplastic diseases are not fully understood. Therefore, the aim of this study was to analyze concentrations and distribution of plasma phospholipids in patients with prostate cancer (PCa) related to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics